This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
by Kanishka Das
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
by Kinjel Shah
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?
by Sundeep Ganoria
Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and future prospects.
Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
by Zacks Equity Research
VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.
AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
by Kinjel Shah
AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.
NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?
by Zacks Equity Research
Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.
Company News for Aug 18, 2025
by Zacks Equity Research
Companies in The News Are: AMAT, UNH, BRK.A, WFC, LLY
Lilly Stock Down 5% This Month: Should You Buy the Dip?
by Kinjel Shah
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
by Zacks Equity Research
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
by Ahan Chakraborty
Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market competition.
Guidance Watch: 2 Companies Bullishly Raising Forecasts
by Derek Lewis
One company remains at the forefront of the AI frenzy, whereas the other has seen insiders dive in post-earnings.
Zacks Investment Ideas feature highlights: IonQ, Hims and Hers, Eli Lilly and TransMedics
by Zacks Equity Research
Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.
3 Unusual Insider Transactions you Should Know About
by Andrew Rocco
While no single indicator can guarantee a stock's performance, the pattern of insider transactions can provide a powerful glimpse into a company's prospects.
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
by Ethan Feller
Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
by Ahan Chakraborty
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly
by Santanu Roy
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
by Ahan Chakraborty
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.
Lilly (LLY) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?
by Kinjel Shah
Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
by Zacks Equity Research
NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
by Sweta Killa
LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.
Stock Market News for Aug 8, 2025
by Zacks Equity Research
U.S. stocks ended mixed on Thursday, with the Dow and the S&P 500 giving up their gains, as investors assessed President Donald Trump's plans to impose hefty tariffs on chip imports and digested the latest batch of corporate earnings.
Markets Lose Momentum, Late Q2 Reports Move Stocks
by Mark Vickery
Indexes fell from their opening bell levels in the green across the board, with a slight surge late.